Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0UL0K
|
|||
Drug Name |
Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1
|
|||
Synonyms |
PMID25539043-Compound-WO2013122897Example51
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
AMGEN INC
|
|||
Structure |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Voltage-gated sodium channel alpha Nav1.5 (SCN5A) | Target Info | Blocker | [1] |
Voltage-gated sodium channel alpha Nav1.7 (SCN9A) | Target Info | Blocker | [1] | |
Target's Patent Info | Voltage-gated sodium channel alpha Nav1.5 (SCN5A) | Target's Patent Info | [1] | |
Voltage-gated sodium channel alpha Nav1.7 (SCN9A) | Target's Patent Info | [1] | ||
KEGG Pathway | Adrenergic signaling in cardiomyocytes | |||
Pathwhiz Pathway | Muscle/Heart Contraction | |||
Reactome | Interaction between L1 and Ankyrins | |||
WikiPathways | SIDS Susceptibility Pathways | |||
Cardiac Progenitor Differentiation |
References | Top | |||
---|---|---|---|---|
REF 1 | Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.